Form DEF 14A FRACTYL HEALTH, INC. For: Aug 24

Mon, 24 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260824/26968191.html

Form DEF 14A FRACTYL HEALTH, INC. For: Aug 24

Mon, 24 Aug 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260824/26968191.html

Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance

Thu, 20 Aug 2026 07:00:00 -0400

BURLINGTON, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will host a virtual Commercial Strategy Day on Tuesday, September 1, 2026 at 11:00 AM ET to discuss the potential commercial opportunity and go-to-market strategy for Revita^®. To register, click here.

The event follows the Company’s positive one-year randomized data from the REMAIN-1 Midpoint Cohort, which showed weight maintenance one year after a

Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance

Thu, 20 Aug 2026 07:00:00 -0400

The event follows the Company’s positive one-year randomized data from the REMAIN-1 Midpoint Cohort, which showed weight maintenance one year after a

Form PRE 14A FRACTYL HEALTH, INC. For: Sep 24

Fri, 14 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260814/26930645.html

Form PRE 14A FRACTYL HEALTH, INC. For: Sep 24

Fri, 14 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260814/26930645.html

Fractyl Health, Inc. (GUTS) Tops Q2 EPS by 9c

Mon, 10 Aug 2026 16:50:45 -0400

Fractyl Health, Inc. (NASDAQ: GUTS) reported Q2 EPS of ($0.16), $0.09 better than the analyst estimate of ($0.25).

For earnings history and earnings-related data on Fractyl Health, Inc. (GUTS) click here.

Form 8-K FRACTYL HEALTH, INC. For: Aug 10

Mon, 10 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260810/26897760.html

Form 8-K FRACTYL HEALTH, INC. For: Aug 10

Mon, 10 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260810/26897760.html

Form 10-Q FRACTYL HEALTH, INC. For: Jun 30

Mon, 10 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260810/26897799.html

Form 10-Q FRACTYL HEALTH, INC. For: Jun 30

Mon, 10 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260810/26897799.html

Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates

Mon, 10 Aug 2026 16:05:00 -0400

One-year REMAIN-1 Midpoint Cohort data show Revita patients maintained up to 84% of prior GLP-1-induced weight loss versus 46% with sham in patients receiving complete duodenal ablations — the first randomized evidence of durable, drug-free weight maintenance

One-year open-label REVEAL-1 Cohort data provide real-world evidence of durable weight maintenance, with patients maintaining approximately 78% of their prior GLP-1-induced weight loss after a single Revita procedure

REMAIN-1 Pivotal Cohort topline data on track for early Q4 2026, paving the way for potential FDA De Novo submission in post-GLP-1 weight maintenance in late Q4 2026

Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates

Mon, 10 Aug 2026 16:05:00 -0400

REMAIN-1 Pivotal Cohort topline data on track for early Q4 2026, paving the way for potential FDA De Novo submission in post-GLP-1 weight maintenance in late Q4 2026

Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026

Mon, 03 Aug 2026 16:05:00 -0400

BURLINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will report financial results for the second quarter 2026 and provide business updates on Monday, August 10, 2026, at 4:30 p.m. ET.

A live webcast of the conference call and presentation can be accessed in the “Events” section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the

Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026

Mon, 03 Aug 2026 16:05:00 -0400

Fractyl Health to Participate in Upcoming Investor Events

Wed, 22 Jul 2026 16:01:00 -0400

BURLINGTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will be participating in the following upcoming investor conferences: